Mercolli Lorenzo, Mingels Clemens, Manzini Giulia, Cumming Paul, Zeimpekis Konstantinos, Xue Song, Alberts Ian, Uehlinger Dominik, Rominger Axel, Shi Kuangyu, Afshar-Oromieh Ali
Department of Nuclear Medicine, Bern University Hospital, University of Bern, Bern, Switzerland;
Department of Nuclear Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.
J Nucl Med. 2023 Oct;64(10):1570-1573. doi: 10.2967/jnumed.123.265577. Epub 2023 Aug 24.
We report the dosimetric evaluation of prostate-specific membrane antigen-based radioligand therapy (RLT) for metastatic prostate cancer in a patient with autosomal-dominant polycystic kidney disease. The patient received hemodialysis during each of 6 RLT cycles while staying as an inpatient. We used voxel dosimetry and blood sampling for the dose calculation. The patient responded well to the RLT, as indicated by the prostate-specific antigen level decreasing from 298 to 7.1 ng/mL. The doses per cycle ranged from 0.19 to 0.4 Gy/GBq for the parotid gland, 0.14 to 0.28 Gy/GBq for the submandibular gland, 0.03 to 0.11 Gy/GBq per kidney, and 0.10 to 0.15 Gy/GBq for the red bone marrow. This case suggests that [Lu]Lu-PSMA-based RLT can be applied successfully and safely to a patient with chronic kidney disease undergoing hemodialysis.
我们报告了对一名患有常染色体显性多囊肾病的转移性前列腺癌患者进行基于前列腺特异性膜抗原的放射性配体疗法（RLT）的剂量学评估。该患者在6个RLT周期的每个周期住院期间均接受血液透析。我们使用体素剂量测定法和血液采样进行剂量计算。前列腺特异性抗原水平从298降至7.1 ng/mL，表明该患者对RLT反应良好。腮腺每个周期的剂量范围为0.19至0.4 Gy/GBq，颌下腺为0.14至0.28 Gy/GBq，每个肾脏为0.03至0.11 Gy/GBq，红骨髓为0.10至0.15 Gy/GBq。该病例表明，基于[Lu]Lu-PSMA的RLT可以成功且安全地应用于正在接受血液透析的慢性肾病患者。
